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-dP/dt were monitored. MBF (mVmin/g) and coronary vascular resislance 
(CVR) was determined by fluorescent microspheres. Myocardial iNOS activ- 
ity (fmol//~g) was assayed by conversion of L-14C-arginlne to L-14C-citrulline 
and NO. Infarcted rabbits developed left ventdcular dysfunction; MBF in the 
surviving myccardium was significantly recfuced, iNOS Inhibition by SMT and 
AG significantly improved myocardial performance and increased MBF in 
infamted rabbits but not in sham animals, 
In conclusion the present study provides evidence that increased iNOS 
formation in MI contributes to myocardial dysfunction; selective modulation 
of this isozyme improves cardiac performance and increases MBF in the 
suwiving myccardium and may be beneficial in the treatment of the disease. 
5:15 
~ Medical Treatment With ACE-Inhibitors Prevents the 
Ischemia-lndoced Activation of  Protein Kinase C in 
Acute Myocardial Infarcl lon 
Ruth H. Strasser, Markus Dahlem, Martin Braun, Ulrike Oehl, 
Rather Marquetant. Univers,ty of Heidelberg, Germany 
In early myocardial ischemia ACE-inhibitorS have been shown to reduce 
compensatory cardiac hypertrophy and possibly to prevent myocardial re- 
modeling. An enzyme which may contribute to these processes might be 
protein kinase C (PKC). Early myocardial ischemia has been shown to in- 
duce an activation of PKC. The mechanisms leading to this activation are not 
known- 
To investigate, ifACE-inhibitors might modulate the ischemia-induced ac- 
tivation of PKC, isolated perfused rat hearts according to the method of Lan- 
geedorff were subjected to myocardial ischamia by stop of perfusion for 2.5 
min. In the ischemic hearts PKC activity increased in the plasma membranes 
(310 :l: 29 to 381:1:18 pmol/min/mg protein) with a concomitant reduction 
of the cytosolic PKC activity. This trenslocetion of PKC is s,+:ggestive of a 
rapid activation of PKC in myocardial ischamia, Prepedusion for 20 rain. 
with two different ACE-inhibitors, Enalapdlat and Ramipdlat (each 10 pg/ml), 
followed by a 2.5 min. episode of ischemia was able to completely prevent 
the ischamia.induced translocetion and activation of PKC. PKC activity beth 
in the particulate and in the cytosolic fraction remained completely unaltered 
after brief periods o! ischemia in the preoence of an effective ACE-inhibition. 
Similarly, pretreatment with Enalapdlat (25-50 pg/kg i.p.) for one week was 
also able to completely prevent an activation of PKC in acute myocardial 
infarction. 
These data demonstrate for the first time that ACE-inhibition pdor to my* 
ocardial ischemia can effectively prevent the ischemia-induce activation of 
PKC. Further studies have to show, if ACE-inhibitors mediate pert of their 
protective ffects via this newly characterized blockade of protein kinase C 
activation in the infarcted heart. 
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4:00 
~ Exercise Hemodynamica in Patients Chronically 
Supported With a Latt Ventricular Device: Results of 
the EVADE Pilot Trial 
Brian Jaskl, Kelley Branch, John Gordon, Robert Adamson, 
Peter Hoagland, I_am/Favrot, Richard Maly, Walter Dembitsky. Sharp 
Memorial HOSp#a/, San Diego, CA 92123 
As a pilot for the Experience with LVAD with Exercise (EVADE) trial, 10 
patients implanted with the Thermo Cardiosystems LVAD (8 pneumatic, 2 
vented alectdc) were assessed (ran ± SD) 46 ± 25 days pest-implant with 
supine bicycle exercise. VAD rate (VR), Fick cardiac (CO) and VAD (VO) 
output, right atrial (RA), pulmonary artery (PA), wedge (PCW), and radial 
artedal (BP) pressures (ram Hg), mixed venous 02 content (PAsat), and 02 
consumption (02) were: 
HR VR BP RA PA 
Rest 87±12 82<-18 94<-13 6±4 17±3 
Exercise 108<-17 107±21 103:J: 13 12:E5 31 :J: 7 
PCW CO (I/m) VO (I/m) PAsat (%) O2(-cc/kg/m ) 
Resi" 5<-3 5.0 ± 1.2 5,4±0.9 67+5 2.8:1:0+4 
Exercise 14±8 7.8 <- 2.5 7.0<-1.4 39±10 8.2 d: 1.7 
With exercise, CO increased more than VO (p < 0.05) and Doppler-echo 
showed LV ejection through the native aortic valve. Peak upright treadmill 
exercise 02 was 14.6 4- 2.9 (p < 0.005 ~,  supine bike). Hemoglobin (Hgb) 
was 10.5:1:1.2. Plasma flee Hgb was not elevated in any patient. 
Thus: 1) Despite postoperative anemia, circulatory reserve allowed exer- 
cise compatible with activities of dally life associated with mederate levations 
in dght and left heart filing pressures. 2) The LV and LVAD operate as ssdos 
pumps at rest, but as parallel pumps at peak exercise when increased left 
heart filling pressure permits LV ejection through the native aortic valve. 3) 
O~ consumption was higher with upright readmill compared to supine bike 
exercise. 
4:15 
I "~ '~ Effec'l o f  Percuteneous Cardlopulmonary Support 
on Coronary Artery Row Velocity 
ToyoJi Nemoto, Kazuo Kimura, Tomoakl Shlmizu, Yasuyuki Mochfda, 
Masami Kosuge, Naomitsu Kujt, Toshiyuki Ishikawa, Naomichi Miyasaki, 
Osamu To~hikubo, Masao Ishii. Yokohama City University, Yokohama, 
Japan 
Purpose of this study was to assess the effect of PCPS on coronary artery 
flow velocity (CAFV) and its waveform, using intravascular Doppler guide 
wire. PCPS were performed as circulatory support for left main trunk (LMT} 
stsnting in two patients and as rosustation measures for bystander Cardio- 
pulmonary arrest in six patients with acute myocardial infarction. The CAFV 
was recorded in normal coronary artery without stenosis (> 25%) dudng 
pump on and off, or during stepwise decrease in pump flow. In the patients 
(n = 2) with normal sinus rhythm after successful LMT stanting, the CAFV 
was normal dudng pump off, and PCPS increased it without changes in its 
waveform pettem. In the patient (n = 1) with ventdcular standstill, PCPS 
increased mean CAFV from zero to 55 cm/sec with non-pulsatile flow. In the 
patients (n = 5) undergoing circulatory-pulmonary resustation, native coro- 
nary flow under ventricular hythm during pump off indicated charactedstic 
findings, such as marked decrease in systolic antegrade flow, appearance 
of abnormal broad systolic retrograde flow (SRF) and rapid deceleration of 
diastolic antegrade flow (DAF). Circulatory assist of PCPS increased mean 
CAFV and improved the efficient coronary circulation, which was indicated 
by OAF minus SRF. In conclusion, PCPS may increase coronary artery flow 
and improve abnormal CAFV waveform impairecl by cardiac dete,-ioralion. 
4:30 
~ Temporary Mechanical Support Wilh the BVS 5000 
Assist Device During Treatment of  Acute Viral 
Myocarditi.s 
Daniel Mare,i, Hi,el Laks, Abbas Ardshali, Bram Amsel, Gregory Couper, 
G. Kimble Jett, Aivaro Galindo, Davis C. Ddnkwater. UCLA Medical Center, 
Los Angeles, California 
Ventricuiar support with the BVS 5000 (Abiomed) has been used as tempe- 
rary circulatory assist for the failing heart. Our purpose is to summarize four 
cases illustrating the role of mechanical unloading in acute myocarditis. 
Four patients aged 16-33 y.o. presented with CHF 4-20 days after a 
flu-like syndrome. All patients were in severe cerdiogenic shock :t: renal and 
liver dysfunction. EF ranged from 5-26%. Indications for ventdcular assist 
were failure of maximal medical treatment with _> two inotmpes :t: IABP. 
Myocardial biopsy revealed acute myocarditis in three patients and severe 
edema in one despite a charactsdstic linical course, Two patients received 
immunotharapy with OKT3. Biventdcular assist was used in three patients 
and left ventricular assist only was used in one. Mean support time was 
0.3 days (7-11). All patients had recovery of myocardial function and were 
discharged from the hospital in good condition. 
Conclusion: The BVS 5000 device provides a safe, simple, and effective 
method to support the circulation during acute myocarditis. We hypothesize 
that this may facilitate myocardial recovery by decompressing the distended 
ventricle. Ventdcular assist devices should be used eady in the presence of 
detsdoration on maximal medical therapy. 
4:45 
~ Computer Model Predicts Alterat ions in Stroke 
Volume After Cardiomyoplasty 
Rashid M. Ahmad, Brian J. DeGuzman, David B. Lautz, Frederick Y. Chert, 
Rite G. Laurence, Lawrence H. Cohn. Brigham & Women's Hospital, 
Goston, MA 02115 
We developed a computer model to predict alterations in SV following dy- 
namic cardiomyoplasty (DCM). The model examined the effects of LV size 
and shape, and degree of latissimus dorei muscle tiber shortening (LDMFS) 
to predict changes in SV. The model provides an explanation as to why 
significant augmentation in SV has not been seen clinicaUy after DCM. Input 
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parameters of the computer model were LV axis-ratio, EDV, and percent 
LDMFS. We compared predictions of the model to currently available ciinicel 
data in patients followed 5 years after DCM 
Months 6 12 24 36 48 60 
Actual SV 33.5 37.8 36.4 39.3 35.0 34,0 
Predicted SV 34.5 36.0 35.5 38.9 39.0 40,5 
The above data used a mean LDMFS of 15%. To achieve an augmented 
SV of 50-70 cc, LDMFS must be 20--25%, respectively. Clinically, despite 
significant reductions in NYHA functional class scores, concomitant improve- 
ments in objective parameters are not seen. The computer model explains 
this discrepancy. At an LDMFS of 15% or less, the muscle wrap under- 
goes contraction with increase in LDM tension, and predominantly provides 
structural support to the dilated, failing LV. 
Thus, we conclude that to achieve significant hemodynamic augmentation, 
in addition to NYHA functional class improvement after DCM in patients with 
dilated cardiomyopathy, an LDMFS of 20°/o or more must be attained. 
5:00 
~-~'~ Reduction of Ischemlc Deviation and Regional ST 
Wall Motion Oysfunction During PTCA of the Left 
Anterior Descending Coronary Artery (LAO) With 
Synchron ized  Coronary  S inus  Retroper fus ion (SRP) 
Alexander Popov, David M. Lasorda, Christopher A. Nlenaber, C.R. Talbert, 
Kirk U Parr, Mitchell W. Krucoff, Eliot Corday, Bryan C. Donohue. Allegheny 
Generel Hospital, Pittsburgh, PA: Cedars-Sinai Medical Center, Los 
Angeles, CA 
To determine the efficacy of SRP in reducing myocardial ischemia associated 
with PTCA, 120 patients (105--  with LAD lesions) undergoing elective PTCA 
were cannulated for SRP. Two randomly assigned PTCA balloon inflations 
- -  with and without SRP - -  were performed for each patient. ECG results 
were presented in ST segment deviation, and echo results were given a 
regional wall motion score 0NMS) defined ~,s Normal (0), Hypokinesia (1), 
Akinesia (2) and Dyskinesia (3). 
Results. 92 patients completed the protocol. The coronary sinus catheteri- 
zation success rate was 85%, with a mean time to enter the coronary sinus of 
12.7 ~ 14.4 minutes. Complications: 2 cases of pedcardial effusion, treated 
with pedcardiocentesis. In 63 patients with LAD lesions who developed is- 
chemia (at least 1 mm ST change, 1 unit of WMS change or 5% ejection 
fraction (EF) change from baseline) WMS dudng SRP supported PTCA vs 
control was 1.54 ± 1.34 units vs 2.49 ± 1,39 units (P < 0.0001). The EF 
decrease from baseline was subsequently -9.0:1: 4.'P/o vs -13.2 ± 5.7% (P 
< 0.001 ). The mean ECG ST deviation for all ischemic LAD patients was 2.61 
:t: 2.73 mm with SRP vs 4.15 • 3.71 without it (p < 0.001). For 21 of these 
patients, with a mean coronary sinus pressure (CSP) above 25 mmHg, the 
ST deviation was 2.06:1:1,83 mm vs 4.59 ± 4.30 (P < 0.002). Conclusion. 
SRP support reduces the development of myocardial ischemia dunng LAD 
angioplasty, with an enhanced reduction in patients with CSP > 25 mmHg. 
5:15 
(7~'~ The Combination o1 Pulmonary Hypertension and 
Right Ventricular Failure Limits Left Ventricular 
Assist Device Pedormance. An Experimental Study 
Ferdinand R. Waldenberger, Bart Meyns, Wiflem Flemeng. Centrum 68 
experimentele Heelkunde n Anaesfhesiofogie, Kathofieke Universiteit 
Leuven, Leuven, Belgium 
Mschanica; and hemndynamic interactions of the heart-lung-unif have been 
accused to strongly influence the performance of a left ventdcular assist 
device (LVAD). In order to investigate this interaction, we designed an exper- 
imental study in anesthetized, open chest animals, 
We performed the study in 55 dogs divided in control group (n = 5) end 5 
groups with mechanical cimulatory support (each n = 10). As assist device 
we used a pneumatic system, the Medos ® HIA-VAD ~ with its pediatric sizes 
(10-ml and 25-ml). In the control group, we induced left ventricular failure 
(LVF) with subsequent occlusions of LAD and CX followed by reperfusion. 
In the next group we supported with an LVAD dudng 90 minutes, starting 
5 minutes after CX occlusion (group II). In the next group, we added right 
ventdcular ischernla by occluding the RCA simultaneously to the CX (group 
III). Those two groups we repeated but with pre-existing acute pulmonary 
hypertension (PHT), induced by the injection of 100 pm glass beads (groups 
IV and V). Group VI was similar to group V (tell and dght ventricular failure 
and PHT), but instead ol a LVAD we used BVAD support. 
In I and V no animal survived the second repodusion period (4 hourS). In fl 
and til (no PHT), all dogs survived in stable conditions. In IV (LVF, PHT), 60% 
survived, In VI with BVAD, only 40=,o survived. In III and V, dudeg occlusion of 
the RCA, the right ventdde stopped contracting and right atrial pressure and 
mean pulmonary pressure equalized. This lead to a significant drop in inflow 
on the left heart side, which still provided sufficient LVAD performance in case 
of absent PHT (111) and lead to death due to "low LVAD output" syndrome 
in V. This "low LVAO Output" syndrome couk:l be partly overcome by BVAD 
support. 
We conclude that RVF and PHT signilicantly influErce LVAD performance 
and can eventually lead to "low LVAD output" syndrome, 
Chronic Ischemi¢ Heart Disease: Clinical 
Trials 
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4:00 
~ Reduced Serum Paraoxonass Activity Is Associated 
With Progression of Atherosclerosls and New 
Clinical Events: Be~flbrate Coronary 
Atherosclerr, sls Intervention Trial 
Jan Regn~trum, Jan Nilsson, Poter Yhtp, Bojen Cercek, Ulf de Felre, 
CarI-Goran Ericson, Sanjay Kaul, Andem Hamsten, Pred]man K. Shah. 
Cedars-Sinai Medical Center, Los Angeles, CA: Karuliaska Institute, 
Stockholm, SweCen 
Paraoxonase is ;)n antioxidant enzyme carded by a subfraction of HDL- 
cholesterol and may contn'but~ to antlat1~erogenic effec~ of HDL. To deter- 
mine whether parasxonase levels are related to progression of atheresclere- 
sis and clinical coronary events, serum p.~raoxonase activity and quantitative 
corur~ry angiographic findings were cemp~red at baseline and after 5 years 
in 81 patients, age < 45 years, who had an acute myccmdiel infarction and 
were randomized to bezafibrate or plec~oo. As the paraoxonase levels were 
similar in the placebo and bezafibrale treated patients at baseline (356 vs 
359 U/L) and at 5 year follow-up (378 vs 399 U/L) the groups were pooled 
for analysis: 
Median Serum Paraoxonaea (U/L) 
Baseline 5 year's 
New Clinical Events: Yes(N = 10) 273 258 
No (N=71) 356* 399" 
New Occlusion: Yes(N = 20) 329 344 
No (N =61) 356" 410" 
New Lesions: YeslN = 74) 352 375 
No (N = 7) 456 507" 
Ho(:lges Lehman test: 95% CI < 0, Yes vs No Group 
Conclusions: Reduced serum paraoxonase activity in patients with new 
cardiac events or angiegraphic evidence of atherosclerosis progression sup- 
ports an antiatherogenic rote of paraoxonese. 
4:15 
~ ' ~  Results of  the Mibefradi l  Ischemla Suppress ion  THai 
(MIST) 
Dan Tzivoni, Shimon Braun, Addanus Scbefliog, isaac Kobrin for the MIST 
Investigators. Shaare Zedek Med. Center, Jerusalem, Israel 
Mibefradii (Mib) is a new once daily benzimidazolyl tetraline calcium an- 
tagonist with negative chronotmpic and no negative lenotropio effects. Its 
antiischemic effect was assessed in 303 patients (20 centers in 7 ceuntdes) 
with proven coronary disease and positive (chest pain and 1 mm ST de- 
pression) exercise test (ET). Exercise and silent ischemia were evaluated by 
repeated El' and 48 hour ambulatory ECG monitoring (AEM). After wash-out 
Baseline Treatment P vs placebo 
ET.~me to STt (s) 
Placebo N = 62 
Mib 25/50 mg N=60 
Mib 50/100 mg N = 60 
Mib 100/150 m0 N=62 
Am 5/10 mg N=59 
Ischem~c episodes (48 h AEM) 
Placebo N = 30 
Mib 20/50 mg N = 35 
Mib 50/100 mg N = 34 
Mib 100/150 mg N = 34 
Am 5/10 mg N=38 
261 299 - 
268 355 0.006 
246 357 < 0.001 
263 385 < 0.001 
264 318 0.136 
5.8 5.2 - 
4.7 2-B 0.069 
5.4 1.7 < 0.001 
6.1 1.3 < 0.001 
4.5 2.3 < 0.036 
